Telephone: (808) 692-1667
National Taiwan University, College of Medicine, Taipei, Taiwan, M.D. 1986 – Medicine
Harvard School of Public Health, Sc.D. 1995 – Virology
Currently, no antiviral or vaccine against dengue virus (DENV) is available to treat or prevent infections with the four serotypes of DENV, the leading cause of arboviral diseases worldwide. Dr. Wang demonstrated that the level and rate of decline of DENV load and virus-containing immune complexes correlated with disease severity, and reported for the first time the quasispecies nature of DENV in humans and mosquitoes. Recently, he focused on the precursor membrane (prM)/envelope (E) proteins of DENV, virus-like particles and antibody responses. He reported the highly conserved stem regions of prM/E proteins are involved in two important steps of replication and are potential targets of antivirals. Moreover, his lab developed a high-throughput dot blot assay for epitope mapping of anti-E antibodies by alanine-substitution mutants of the surface-exposed E residues. These findings have significant implications for dengue pathogenesis and vaccine development.